NCT02377752 - A Study of Olaratumab in Japanese Participants With Advanced Cancer | Biotech Hunter

Enrollment

25

Participants

Timeline

Start Date

March 23, 2015

Primary Completion Date

August 27, 2018

Study Completion Date

January 14, 2020

Conditions

Neoplasm

Interventions

BIOLOGICAL

Olaratumab

Administered IV

DRUG

Doxorubicin

Administered IV

Trial Locations (4)

104-0045

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician., Chūōku

135-8550

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician., Kōtoku

466-8560

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician., Nagoya

565-0871

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician., Suita-shi